Since it has been shown that various PDEs, i.e., PDE1, PDE3, PDE4, PDE5 and PDE7, are implicated in the pathogenesis of asthma or in COPD [27,34], research has been directed to develop inhibitors that could affect the various isoforms, while maintaining high selectivity for PDEs. This evidence concerns the gene PDE4A and asthma.